Protease inhibitors, including those used for hep C, and various other drugs may cause drug-drug interactions with statins.

Researchers compared direct-acting-antiviral treatment outcomes between those with and without a history of liver cancer.

In an analysis of the liver health of a cohort of HIV/hep B–coinfected people, one third had significant fibrosis.

This holds true regardless of how long they’ve had HIV or whether they’re on antiretrovirals.

Non-alcoholic steatohepatitis, or NASH, is a form of non-alcoholic fatty liver disease.

Researchers say given the many associated downsides and risks, opioids should not be a first choice for chronic noncancer pain.

Differences in the severity of the opioid epidemic are likely partial drivers of such variations.

The FDA’s revision was based on two randomized trials of Viread (tenofovir disoproxil fumarate) use in 2- through 11-year-olds.

What’s more, such treatment is linked to remission of non–Hodgkin lymphoma.

In a cohort of British individuals who contracted hep C as children, one third developed cirrhosis, at a median age of 32 years old.